Small cancer risk reported with bone-strengthening drugs

The FDA mentions a few dozen cases of esophageal cancer in patients who took Fosamax, Actonel or Boniva. And a dentist sees a high incidence of osteonecrosis of the jaw. The family of bone-strengthening drugs called bisphosphonates -- best known by the brand names Fosamax, Actonel and Boniva -- pose a small risk of causing esophageal cancer, a Food and Drug Administration official reported Thursday in a letter to the New England Journal of Medicine.

Read the whole article on LA Times - Science

More from LA Times - Science